BioLineRx Ltd. (BLRX) Income Statement Analysis

See more : Hazer Group Limited (HZRGF) Income Statement Analysis – Financial Results

Complete financial analysis of BioLineRx Ltd. (BLRX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of BioLineRx Ltd., a leading company in the Biotechnology industry within the Healthcare sector.

You may be interested

BioLineRx Ltd. (BLRX)

Industry: Biotechnology

Sector: Healthcare

Website: https://www.biolinerx.com

About BioLineRx Ltd.

BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials for the treatment of metastatic pancreatic adenocarcinoma patients, and Phase 1b clinical trials in patients with acute respiratory distress syndrome secondary to COVID-19 and other respiratory viral infections, as well as for the treatment of solid tumors and acute myeloid leukemia. It is also developing AGI-134, an immuno-oncology agent, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of skin lesions. The company has collaboration agreement with MSD for the cancer immunotherapy field; MD Anderson Cancer Center to investigate the combination of Motixafortide with KEYTRUDA (pembrolizumab) in pancreatic cancer; and licensing arrangement with Perrigo Company plc for over-the-counter sale of BL-5010. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.

Metric	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010
Revenue	4.80M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	113.16M	113.16M	63.91M	31.89M
Cost of Revenue	3.69M	654.00K	702.00K	934.00K	940.00K	451.00K	480.68K	481.89K	440.89K	0.00	0.00	0.00	22.62M	7.21M
Gross Profit	1.11M	-654.00K	-702.00K	-934.00K	-940.00K	-451.00K	-480.68K	-481.89K	-440.89K	0.00	113.16M	113.16M	41.29M	24.69M
Gross Profit Ratio	23.08%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	100.00%	100.00%	64.60%	77.40%
Research & Development	12.52M	17.63M	19.47M	18.17M	23.44M	19.81M	19.51M	11.18M	11.49M	10.90M	12.65M	17.21M	11.20M	15.49M
General & Administrative	16.64M	5.07M	4.27M	3.84M	3.74M	4.41M	4.04M	3.95M	3.65M	3.49M	3.68M	3.71M	3.34M	4.14M
Selling & Marketing	14.59M	6.46M	1.00M	840.00K	857.00K	1.36M	1.69M	1.35M	1.00M	1.46M	1.18M	863.77K	869.15K	1.30M
SG&A	31.23M	11.53M	5.27M	4.68M	4.60M	5.77M	5.73M	5.31M	4.65M	4.95M	4.86M	4.57M	4.21M	5.44M
Other Expenses	7.05M	5.67M	42.00K	70.00K	78.00K	27.00K	-260.00K	7.00K	153.00K	2.81M	-280.83K	-322.27K	0.00	50.17K
Operating Expenses	50.80M	29.16M	24.78M	22.93M	28.11M	25.61M	25.24M	16.51M	16.20M	15.85M	17.63M	21.83M	15.41M	20.98M
Cost & Expenses	54.49M	29.16M	24.78M	22.93M	28.11M	25.61M	25.24M	16.51M	16.20M	15.85M	17.63M	21.83M	15.41M	28.19M
Interest Income	2.01M	694.00K	559.00K	236.00K	777.00K	719.00K	1.17M	480.00K	457.00K	3.28M	746.59K	2.36M	3.34M	861.33K
Interest Expense	2.17M	2.16M	984.00K	1.47M	1.83M	21.00K	21.00K	14.00K	15.00K	411.67K	20.67K	25.96K	1.12M	16.63K
Depreciation & Amortization	1.38M	654.00K	702.00K	934.00K	940.00K	451.00K	480.68K	481.89K	441.00K	246.54K	329.36K	407.93K	410.67K	511.28K
EBITDA	-57.06M	-28.50M	-25.35M	-21.99M	-27.17M	-25.15M	-23.83M	-15.34M	-13.94M	-10.79M	-16.70M	-19.38M	-13.59M	4.21M
EBITDA Ratio	-1,188.77%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-14.88%	-18.90%	-23.47%	20.90%
Operating Income	-49.69M	-29.16M	-24.78M	-22.93M	-28.11M	-25.61M	-25.24M	-16.51M	-16.20M	-15.85M	-17.63M	-21.83M	-15.41M	3.70M
Operating Income Ratio	-1,035.29%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-15.58%	-19.29%	-24.11%	11.61%
Total Other Income/Expenses	-10.92M	4.21M	-2.28M	-7.09M	2.67M	2.64M	888.00K	672.00K	1.80M	6.18M	-13.16K	1.37M	1.39M	-1.61M
Income Before Tax	-60.61M	-24.95M	-27.05M	-30.02M	-25.45M	-22.96M	-24.35M	-15.84M	-14.40M	-10.17M	-17.64M	-20.42M	61.52M	2.10M
Income Before Tax Ratio	-1,262.79%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-15.59%	-18.04%	96.26%	6.57%
Income Tax Expense	1.00K	-6.08M	1.09M	911.00K	1.36M	-4.46M	-888.00K	-672.00K	-1.80M	-5.68M	15.79K	-1.42M	-2.22M	1.61M
Net Income	-60.61M	-18.87M	-28.14M	-30.93M	-26.81M	-18.51M	-24.35M	-15.84M	-14.40M	-10.17M	-17.64M	-20.42M	-13.19M	2.10M
Net Income Ratio	-1,262.79%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-15.59%	-18.04%	-20.63%	6.57%
EPS	-0.94	-0.37	-0.64	-1.84	-2.75	-2.56	-4.06	-4.23	-4.20	-4.71	-11.77	-18.08	-16.00	2.54
EPS Diluted	-0.94	-0.37	-0.64	-1.84	-2.75	-2.56	-4.06	-4.23	-4.20	-4.71	-11.77	-18.08	-16.00	2.54
Weighted Avg Shares Out	64.22M	51.60M	44.20M	16.86M	9.76M	7.24M	6.00M	3.74M	3.43M	2.16M	1.50M	1.13M	823.91K	823.41K
Weighted Avg Shares Out (Dil)	64.22M	51.60M	44.20M	16.86M	9.76M	7.24M	6.00M	3.74M	3.43M	2.16M	1.50M	1.13M	823.91K	830.31K

BioLineRx Announces Closing of Exclusive License Agreement to Motixafortide in Asia and Concurrent Strategic Equity Investment

October 12, 2023prnewswire.com

- License agreement includes $15 million upfront, up to $50 million in potential development and regulatory milestones; up to ~$200 million in potential commercial milestones, and tiered double-digit royalties on sales - - Gloria Biosciences expected to begin bridging study...

BioLineRx Announces Encouraging Data from Pilot Phase of Phase 2 Combination Clinical Trial with Motixafortide in First-Line Pancreatic Cancer (PDAC)

September 28, 2023prnewswire.com

- 6 of 11 Patients in the Pilot Phase Experienced a Partial Response, with 4 Confirmed; One Patient Experienced Resolution of the Hepatic Metastatic Lesion - - Data Presented at AACR Special Conference on Pancreatic Cancer - - Multi-Center, Randomized...

BioLineRx Announces Acceptance of Oral Presentation on Pilot Phase Data from Phase 2 Combination Clinical Trial with Motixafortide in First-Line PDAC at AACR Special Conference on Pancreatic Cancer

September 19, 2023prnewswire.com

Abstracts to be Published on American Association of Cancer Research (AACR) Virtual Meeting Platform at 5:30 pm EDT on Wednesday, September 27, 2023 Oral Presentation on Thursday, September 28, 2023, in Boston, Massachusetts TEL AVIV, Israel , Sept. 19, 2023...

3 Hot Penny Stocks To Watch Before The September Fed Meeting

September 18, 2023pennystocks.com

Penny stocks represent an exciting yet risky path to profits for active investors. Defined as stocks priced under $5 per share, these cheap equities boast the potential for astronomical returns on minimal investments.

Assessing BioLineRx As A Buy After Drug Approval

September 18, 2023seekingalpha.com

BioLineRx has received approval for their stem cell mobilizing compound, motixafortide, for certain forms of blood cancer. The compound has shown impressive results in mobilizing stem cells in patients, with a high success rate in optimal stem cell collection. However,...

BioLineRx rallies on FDA approval of Aphexda with Filgrastim

September 11, 2023proactiveinvestors.com

Bioline RX Ltd (NASDAQ:BLRX) shares jumped at the market open on Monday after the US Food and Drug Administration approved the use of Aphexda (motixafortide) in combination with filgrastim for patients with multiple myeloma, a type of bone marrow cancer. The...

BioLineRx Ltd. (BLRX) Q2 2023 Earnings Call Transcript

August 30, 2023seekingalpha.com

BioLineRx Ltd. (NASDAQ:BLRX ) Q2 2023 Earnings Conference Call August 30, 2023 7:30 PM ET Company Participants John Lacey - Head of Investor Relations and Corporate Communications Phil Serlin - Chief Executive Officer Mali Zeevi - Chief Financial Officer Holly...

BioLineRx Reports Second Quarter 2023 Financial Results and Recent Corporate and Portfolio Updates

August 30, 2023prnewswire.com

- On Track for September 9, 2023 PDUFA Target Action Date on NDA for Motixafortide in Stem Cell Mobilization (SCM) for Autologous Transplantation in Multiple Myeloma (MM) - - Signed Exclusive License Agreement to Motixafortide in Asia Region with Concurrent...